2011, Number 4
PDF size: 105.26 Kb.
ABSTRACTThe treatment of patients with chronic myeloid leukemia (CML) has changed . Busulfan and hidroxiurea are used only in some parts of the world. The allogeneic transplant is used only in selected cases by means mainly of reduced intensity conditioning. Imatinib, a tyrosine kinase inhibitor , remains the best current standard first-line therapy for patients with chronic phase of CML. And it has been suggested that at least some. Patients, CML can be cured using imatinib. The second generation inhibitors: dasatinib, nilotinib and bosutinib are very effective and could be used in selected cases. More studies are needed, in the so called third world, in order to find the best treatment applicable to our economy and special and different patients.
Hochhaus A, Weisser A, La Rosee P, et al. Molecular heterogeneity in complete cytogenetic responders after interferonalpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and UK MRC CML Study Group. Blood 2000;95:62-66.
Giles, F, le Coutre, P, Bhalla K, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy (abstract). Blood 2006;108:2170.
Cortes J, Kantarjian HM, Baccarani M, et al. A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. Blood 2006;108:54a.
Gratwohl A, Brand R, Apperley I, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, log-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-521.